康龙化成(西安)科技发展有限公司

康龙化成（股票代码：300759.SZ、3759.HK）是国际领先的生命科学研发和生产服务企业。自2004年成立以来，康龙化成一直致力于人才培养和设施建设，为包括小分子、大分子和细胞与基因治疗药物在内的多疗法药物研发打造了一个贯穿药物发现、临床前及临床开发全流程的研发生产服务体系。康龙化成在中国、美国、英国均开展运营，拥有21,000多名员工，向北美、欧洲、日本和中国的合作伙伴提供研发解决方案并与之保持良好的合作关系。康龙化成（西安）科技发展有限公司成立于2021年，注册资本4.5亿元，是康龙化成（北京）新药技术股份有限公司的全资子公司，是公司迄今为止在中国西北地区投资建设的最大生命健康产业项目，旨在打造一个专注于新药研发实验室服务阶段的全球领军平台。

Pharmaron (Stock Codes: 300759.SZ, 3759.HK) is an internationallyleading enterprise providing lifescience R&D and manufacturing services. Founded in 2004, Pharmaron has long been committed to talent cultivation and facility development. It has built an endtoend R&D and manufacturing service system covering drug discovery, preclinical and clinical development for multitherapy pharmaceuticals including smallmolecule drugs, largemolecule drugs, as well as cell and gene therapies. Operating in China, the United States and the United Kingdom, the company employs more than 21,000 staff. It delivers R&D solutions to and maintains sound partnerships with collaborators across North America, Europe, Japan and China. Pharmaron (Xi’an) Technology Development Co., Ltd. was established in 2021 with a registered capital of RMB 450 million. As a whollyowned subsidiary of Pharmaron Beijing Co., Ltd., it represents the largest lifehealth industrial project the Group has ever invested in and constructed in Northwest China. It aims to build a globally leading platform focusing on laboratorystage services for newdrug research and development.

官网：www.pharmaron.com